IMR Press / EJGO / Special Issues / 1619668830973

The Role of Surgery in Ovarian Cancer

Section: Ovarian Cancer
Submission deadline: 30 December 2021
Special Issue Editors
Giuseppe Trojano, MD
Chief Consultant Gynecologist and Obstetrician, Department of Obstetrics and Gynaecology 2, AOU Policlinico Consorziale Bari University Hospital, Azienda Sanitaria Matera, Italy
Interests: Cancer; Ovarian cancer; Cancer diagnostics; Cancer biomarkers; Cancer prevention; Clinical oncology
Olga Ostrovsky, PhD
Department of Surgery, Division of Surgical Research, Cooper University Healthcare, Camden, NJ, USA
Interests: Tissue repair by usage of adipose-derived stem cells; Regulation and prevention of ovarian cancer and metabolic diseases by epigenetic therapy; Role of cannabinoids in post-surgical tissue regeneration and pain control; Regulatory Check points of cell proliferation; Differentiation and regrowth
Special Issue Information

Dear Colleagues,
Ovarian cancer is the second most common cause of gynecologic cancer death in women around the world. Primary debulking surgery followed by platinum/taxane-based chemotherapy is the standard of care in advanced EOC. Surgery and platinum‐based chemotherapy are the cornerstones of multimodal treatment in the primary disease setting. The most important prognostic factor for survival is no residual tumour after primary debulking surgery. Two randomised clinical trials comparing Primary debulking surgery and chemotherapy with neoadjuvant chemotherapy (NACT) followed by interval debulking surgery (IDS) showed similar survival with a low operative morbidity when NACT and interval debulking surgery were used. The choice between PDS and chemotherapy or NACT and IDS is controversial. Further research is needed on how to select patients for PDS or NACT, including better and validated imaging or laparoscopic scoring systems and algorithms to predict operative morbidity. Systematic pelvic and para-aortic lymphadenectomy in patients with advanced EOC with both intra-abdominal complete resection and clinically negative lymph nodes does not improve overall or progression-free survival. Fertility sparing surgery In young patients with well-differentiated or low-grade, stage IA disease can be considered. Uterus and contralateral ovary can be left in place pending pathology review of the removed tissues and further counseling with the patient.  Selection of patients for fertility preservation requires careful consideration of the risks and benefits. The likelihood of cure is high for women with stage IA disease, but residual disease and subsequent recurrence are associated with low likelihood of salvage.

Dr. Giuseppe Trojano and Dr. Olga Ostrovsky

Guest Editors

Keywords
Ovarian cancer
Primary debulking surgery
Fertility sparing surgery
Platinum/taxane-based chemotherapy
Manuscript Submission Information

Manuscripts should be submitted via our online editorial system at https://imr.propub.com by registering and logging in to this website. Once you are registered, click here to start your submission. Manuscripts can be submitted now or up until the deadline. All papers will go through peer-review process. Accepted papers will be published in the journal (as soon as accepted) and meanwhile listed together on the special issue website. Research articles, reviews as well as short communications are preferred. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office to announce on this website.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts will be thoroughly refereed through a double-blind peer-review process. Please visit the Instruction for Authors page before submitting a manuscript. The Article Processing Charge (APC) in this open access journal is 1500 USD. Submitted manuscripts should be well formatted in good English.

Back to top